Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
Integrated Regional Information Networks - September 15, 1999
Hopes of an early vaccine were buoyed by the disclosure that production had started on the first HIV-vaccine to be developed in collaboration with African researchers, and that early clinical trials on human beings would begin next January in Britain.
"Researchers from the University of Nairobi are working with vaccine scientists from Oxford University in the UK to produce a vaccine which targets the strain of HIV most prevalent in East Africa - the clade A genetic sub-type," Nick Gouedde of the International AIDS Vaccine Initiative (IAVI) said.
The organisation - the UNAIDS Collaborating Centre for Vaccine Development - was also investing in a joint American-South African vaccine scheduled to move into human trials during the year 2000.
"IAVI believes that the simultaneous testing of a wide variety of different vaccine approaches will yield the fastest path to safe and effective AIDS vaccines," Gouedde said.
Delegates to the eleventh International Conference on AIDS and STDs in Africa (ICASA) have expressed concern at the lack of accessibility, related to cost, of antiretroviral drugs that reverse or mitigate the effects of HIV/AIDS in the worldÆs poorer countries.
HIV/AIDS, which delegates described as a national disaster in many developing countries, has claimed an estimated 11 million lives in sub-Saharan Africa and infected a further 22 million people.
On Tuesday, the World Bank said it would respond to the AIDS pandemic in the worldÆs poorer countries by making it the centre of its all its development efforts there.
The Bank said it could provide up to US $3 billion to fighting AIDS in sub-Saharan Africa annually under the initiative.
990915
IR990903
Copyright © 1999 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980 – 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .